Allegro Inks Second Asian Alliance For Luminate
This article was originally published in PharmAsia News
Allegro has secured a second Asian partner for its novel integrin peptide therapy for ophthalmic disorders, linking with Hanmi for the Korean and Chinese markets.
You may also be interested in...
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie’s Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.
Amid simmering regional geopolitical tensions, speakers at a recent conference highlighted the multiple benefits of conducting clinical trials in Taiwan, while pointing to what more could be done to improve the local ecosystem.